KD 025

Drug Profile

KD 025

Alternative Names: KD-025; SLX-2119

Latest Information Update: 02 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Surface Logix
  • Developer Kadmon Pharmaceuticals; Quotient Sciences
  • Class Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Indazoles; Quinazolines; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graft-versus-host disease; Idiopathic pulmonary fibrosis; Plaque psoriasis
  • Phase I Autoimmune disorders; Scleroderma
  • Discontinued Non-alcoholic steatohepatitis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 02 Jul 2018 Chemical structure information added
  • 08 May 2018 Kadmon Corporation plans a phase II trial in Scleroderma in 2018
  • 08 May 2018 Kadmon Corporation plans a pivotal phase II trial in Graft-versus-host disease in USA in the third quarter of 2018, based on FDA guidance received in a Type C meeting (9243347; 9237683; 9235098)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top